<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098213</url>
  </required_header>
  <id_info>
    <org_study_id>PSOTHERMES</org_study_id>
    <nct_id>NCT02098213</nct_id>
  </id_info>
  <brief_title>Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis</brief_title>
  <official_title>Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis, a Randomized, Controlled, Open Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Francaise pour la Recherche Thermale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Floralis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Francaise pour la Recherche Thermale</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of quality of life after Spa therapy (4 ½ months follow-up) in the treatment of
      plaque psoriasis: Spa versus usual care in patients with plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is one of the most common skin diseases, affecting 2-3% of the general population;
      more than 1 million people in France.

      This auto-immune erythematosquamous inflammatory dermatosis occurs on a particular genetic
      background and has a chronic course. Psoriasis has a history as an indication for
      dermatological spa treatment (water cures in the Dead Sea). As these treatments are a
      combination of balneotherapy and heliotherapy, many recent studies have attempted to assess
      the value and position the relative benefit of each therapeutic element. Over the last four
      decades various different phototherapy techniques have been widely used in the treatment of
      psoriasis. The thermal option for many psoriasis patients depends on personal choice, or
      their doctor's or dermatologist's recommendation. In 1994 only one third of the 16,875 spa
      treatments for dermatological conditions (about 5625 cures) were for psoriasis, suggesting
      that spa treatment is underused as a treatment for psoriasis. Nobody can challenge the
      therapeutic contribution of biotherapy in the treatment of anatomically destructive diseases
      such as rheumatoid arthritis and psoriatic arthritis, but the use of these treatments is not
      without risk and economic impact. There is thus a need for less intensive treatments that
      have little risk of serious side effects and are less expensive.

      The use of spa therapy in psoriasis should be understood as complementary and not an
      alternative to all other treatments. The choice of treatment is guided by the patient's
      characteristics and pathology (concomitant diseases, extent of lesions, treatment history)
      and the specialty (adverse effects, cumulative dose). In psoriasis it may be necessary to use
      different lines of treatment because psoriasis is a lifetime disease. Side effects of
      systemic treatments such as biotherapy, cyclosporine, methotrexate, synthetic retinoids, and
      also phototherapy (PUVA and UVB) are cumulative over time. A course of spa treatment should
      allow a respite before resorting to other systemic therapy.

      However, the spa dermatology still suffers from a lack of large-scale evaluation and
      especially an objective assessment using reliable methodologies that limit bias. This is the
      purpose of this study.

      There are no randomized controlled multicenter clinical trials evaluating spa treatment for
      psoriasis, although an Italian non-randomized study included a few dozen patients and
      confirmed the clinical benefit of the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Taking into account the hypothesis of a proportion of patients with a DLQI≤10 (absence of repercussion or low impact of psoriasis on quality of life) of 25% at 4 months 1/2 in the arm immediate spa treatment versus 10% in the usual care group (late spa treatment), 113 patients per group is required, with an alpha 5% risk and a power of 80 %. Given the risk of potential patients lost to follow-up estimates of 15%, we plan to include 130 patients per randomisation group, so 260 patients in total.
According to the protocol submitted to authorities, given the uncertainties of necessary hypothesis, a re-evaluation of the number of subjects required after the first 100 inclusions is planned. This reassessment will be carried out without intermediate analysis but in view of the results observed for the primary endpoint in mean and standard deviation (event driven).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dermatology Quality of Life Index (DQLI)</measure>
    <time_frame>4 ½ months after randomisation</time_frame>
    <description>proportion of patients with a score ≤ 10 at 4½ months in each arm of the study, spa treatment versus usual care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific Quality Of Life</measure>
    <time_frame>4 1/2, 6, 9 and 12 months after randomisation</time_frame>
    <description>proportion of patients in each arm of the study (spa treatment versus usual care) for the following specific dermatology questionnaires : DLQI score ≤ 10 at 6, 9 and 12 months and VQ Dermato score &gt; 35 at 4 1/2, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Quality Of Life</measure>
    <time_frame>4 1/2, 6, 9 and 12 months after randomisation</time_frame>
    <description>EuroQOL 5D questionnaire at 4 1/2, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit of the psoriasis</measure>
    <time_frame>4 1/2, 6, 9 and 12 months after randomisation</time_frame>
    <description>proportion of patients with a PASI (Psoriasis Area and Severity Index) 50 and PASI 75 at 4½, 6, 9 and 12 months in each arm of the study, spa treatment versus usual care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain and pruritus</measure>
    <time_frame>4 1/2, 6, 9 and 12 months after randomisation</time_frame>
    <description>Self-administered questionnaire with Visual Analogue Scale for pain and for pruritus at 4 1/2, 6, 9, 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment follow up</measure>
    <time_frame>4 1/2, 6, 9 and 12 months after randomisation</time_frame>
    <description>Assessment of topical treatments within 12 months (number of tubes used per month)
Number of phototherapy sessions
Use of conventional systemic therapies (acitretin, methotrexate, cyclosporine) (number of weeks of treatment and dosage)
Number of weeks of treatment by biotherapy
Reduction in the use of the health care system (Number of hospitalizations and specialized consultations in connection with psoriasis or not) within 12 months
Reports on the use of complementary and alternative medicines within12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's examination</measure>
    <time_frame>4 1/2, 6, 9 and 12 months after randomisation</time_frame>
    <description>Impact of the spa treatment on overall metabolism indicators in the year
Will be collected at 4 1/2, 6, 9 and 12 months in the two groups:
height an weight (BMI calculation)
Waist measurement
Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>4 1/2, 6, 9 and 12 months after randomisation</time_frame>
    <description>Evaluation of all adverse events attributable to treatment, or not, according to the usual criteria of pharmacovigilance in clinical trials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress evaluation</measure>
    <time_frame>4 1/2, 6, 9 and 12 months after randomisatio</time_frame>
    <description>self administered questionnaire (PSS: Assessment of stress) at inclusion in the study only</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Immediate Spa treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three week course of spa treatment soon after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Spa treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Three week course of spa treatment soon after 4,5 months visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immediate spa treatment</intervention_name>
    <description>soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)</description>
    <arm_group_label>Immediate Spa treatment</arm_group_label>
    <other_name>Spa treatment soon after randomisation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Late Spa treatment</intervention_name>
    <description>soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)</description>
    <arm_group_label>Late Spa treatment</arm_group_label>
    <other_name>Spa treatment after 4,5 months visit in the study</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both sexes, over 18 years of age, patients with plaque psoriasis for more than one
             year diagnosed by a dermatologist

          -  Stable treatment in the last 6 months

          -  DLQI score &gt; 10

          -  patients volunteering for spa treatment within 6 weeks

          -  consenting to participate to the study with informed consent form signed after
             appropriate information

          -  Affiliation to the French social security system or equivalent

        Exclusion Criteria:

          -  Pregnancy, parturient or breast feeding

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Refusal of consent

          -  Refusal of spa treatment

          -  Contra-indication to spa treatment

          -  Phototherapy in the last 3 months

          -  Guttate, pustular or erythrodermic psoriasis Isolated nail psoriasis

          -  Spa therapy in the past year

          -  Person deprived of liberty or under legal guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie MB BEYLOT-BARRY, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bordeaux University Hospital - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Luc JB BOSSON, Professor</last_name>
    <phone>0033476765040</phone>
    <email>jean-luc.bosson@imag.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carole CR ROLLAND</last_name>
    <phone>0033476765040</phone>
    <email>carole.rolland@univ-grenoble-alpes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Station Thermale Avene</name>
      <address>
        <city>Avene</city>
        <state>Languedoc-Rousillon</state>
        <zip>34260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier DG GUERERO, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thermes de Molitg les bains</name>
      <address>
        <city>Molitg</city>
        <state>Languedoc-Roussillon</state>
        <zip>66500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick PP POLFLIET, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thermes La Roche Posay</name>
      <address>
        <city>La Roche Posay</city>
        <state>Poitou-Charentes</state>
        <zip>86270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Asène AJ JELIASKOFF, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Les thermes de ST-GERVAIS</name>
      <address>
        <city>Le Fayet</city>
        <state>Rhône-Alpe</state>
        <zip>74190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Radostina RB BACHVAROVA STOYANOVA, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Etablissement thermal d'Uriage</name>
      <address>
        <city>Uriage</city>
        <state>Rhône-Alpe</state>
        <zip>38410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Murielle MB BOURGEOIS CLAVIER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol. 2008 Sep-Oct;26(5):546-53. doi: 10.1016/j.clindermatol.2007.10.023. Review.</citation>
    <PMID>18755374</PMID>
  </reference>
  <reference>
    <citation>Kazandjieva J, Grozdev I, Darlenski R, Tsankov N. Climatotherapy of psoriasis. Clin Dermatol. 2008 Sep-Oct;26(5):477-85. doi: 10.1016/j.clindermatol.2008.05.001. Review.</citation>
    <PMID>18755366</PMID>
  </reference>
  <reference>
    <citation>ALT J, NONCLERCQ E. [Treatment of psoriasis by ultraviolet and photosensitizers]. Bull Soc Fr Dermatol Syphiligr. 1953 Jul-Oct;60(4):343-5. Undetermined Language.</citation>
    <PMID>13115903</PMID>
  </reference>
  <reference>
    <citation>Grupper C, Bourgeois-Spinasse J, Eisenmann D. [Treatment of psoriasis in 1970]. Cah Med. 1970 Sep;11:Suppl:15-20. French.</citation>
    <PMID>5454618</PMID>
  </reference>
  <reference>
    <citation>Oddoze L, Témime P, Marchand JP, Benne M. [Combined oral meladinine and ultraviolet rays in the treatment of psoriasis. (Preliminary note)]. Bull Soc Fr Dermatol Syphiligr. 1967;74(5):609-10. French.</citation>
    <PMID>5587899</PMID>
  </reference>
  <reference>
    <citation>SOLOMON WM, NETHERTON EW, NELSON PA, ZEITER WJ. Treatment of psoriasis with Goeckerman technic. Arch Phys Med Rehabil. 1955 Feb;36(2):74-7.</citation>
    <PMID>13229486</PMID>
  </reference>
  <reference>
    <citation>Young E. Ultraviolet therapy of psoriasis: a critical study. Br J Dermatol. 1972 Oct;87(4):379-82.</citation>
    <PMID>4562168</PMID>
  </reference>
  <reference>
    <citation>van de Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol. 2001 Jun;26(4):356-61. Review.</citation>
    <PMID>11422189</PMID>
  </reference>
  <reference>
    <citation>Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol. 1993 Mar;28(3):454-9.</citation>
    <PMID>8445062</PMID>
  </reference>
  <reference>
    <citation>Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S118-24. Review.</citation>
    <PMID>12894135</PMID>
  </reference>
  <reference>
    <citation>Tabolli S, Calza A, Di Pietro C, Sampogna F, Abeni D. Quality of life of psoriasis patients before and after balneo -- or balneophototherapy. Yonsei Med J. 2009 Apr 30;50(2):215-21. doi: 10.3349/ymj.2009.50.2.215.</citation>
    <PMID>19430554</PMID>
  </reference>
  <reference>
    <citation>Grob JJ, Auquier P, Martin S, Lançon C, Bonerandi JJ. Development and validation of a quality of life measurement for chronic skin disorders in french: VQ-Dermato. The RéseaudEpidémiolo gie en Dermatologie. Dermatology. 1999;199(3):213-22.</citation>
    <PMID>10592400</PMID>
  </reference>
  <reference>
    <citation>Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410.</citation>
    <PMID>22250239</PMID>
  </reference>
  <reference>
    <citation>Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009 Oct;23 Suppl 2:1-70. doi: 10.1111/j.1468-3083.2009.03389.x. Erratum in: J Eur Acad Dermatol Venereol. 2010 Jan;24(1):117-8.</citation>
    <PMID>19712190</PMID>
  </reference>
  <reference>
    <citation>Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008 Nov;159(5):997-1035. doi: 10.1111/j.1365-2133.2008.08832.x. Epub 2008 Sep 15. Review.</citation>
    <PMID>18795920</PMID>
  </reference>
  <reference>
    <citation>Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, Li S, Kim KJ, Kim TY, Choi JH, Youn JI; PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011 Sep;63(3):154-63. doi: 10.1016/j.jdermsci.2011.05.005. Epub 2011 May 20.</citation>
    <PMID>21741220</PMID>
  </reference>
  <reference>
    <citation>Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003 Oct 8;1:53.</citation>
    <PMID>14613569</PMID>
  </reference>
  <reference>
    <citation>Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006 Sep 27;4:71.</citation>
    <PMID>17005043</PMID>
  </reference>
  <reference>
    <citation>Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44.</citation>
    <PMID>357213</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plaque psoriasis</keyword>
  <keyword>DLQI</keyword>
  <keyword>VQ Dermato</keyword>
  <keyword>PASI</keyword>
  <keyword>PASI change</keyword>
  <keyword>phototherapy</keyword>
  <keyword>balneotherapy</keyword>
  <keyword>hydrotherapy</keyword>
  <keyword>Euroquol EQ 5d scale</keyword>
  <keyword>Visual analogic scale</keyword>
  <keyword>SPA treatment Scale</keyword>
  <keyword>PSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

